Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
- PMID: 20505526
- PMCID: PMC2978283
- DOI: 10.1097/MCG.0b013e3181dd1348
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
Abstract
Goals and background: The recently developed histologic scoring system for nonalcoholic fatty liver disease (NAFLD) by the nonalcoholic steatohepatitis (NASH) Clinical Research Network (CRN) is becoming increasingly popular. However, its generalizability to a community setting has not been evaluated. We conducted a study to compare a community general pathologist to an expert hepatopathologist in assessing NAFLD using the NASH CRN scoring system.
Study: Forty-eight consecutive patients with suspected NAFLD underwent liver biopsy. Histologic features of interest such as steatosis, lobular inflammation, balloon degeneration, fibrosis, NAFLD Activity Score (NAS), and the presence of NASH were scored in a blinded fashion by the 2 pathologists on 2 separate occasions 3 months apart.
Results: The mean (± SD) length of the liver biopsy samples was 25 ± 5 mm. Interobserver agreement (κ) between 2 pathologists was 0.62 (0.45-0.80) for steatosis, 0.44 (0.23-0.65) for lobular inflammation, 0.25 (0.11-0.38) for ballooning, 0.40 for NAS (0.28-0.52), and 0.35 (0.19-0.52) for fibrosis. The 2 pathologists diagnosed "definite NASH" in a similar proportion of patients (56% vs. 57%), but their interobserver agreement was only 0.46 (0.24-0.67) as they both diagnosed different levels of NASH (borderline vs. definite) in different subjects. Intraobserver agreement was generally comparable for steatosis, lobular inflammation, NAS, and diagnosis of NASH, but not for fibrosis.
Conclusions: Clinically important differences exist between community general pathologist and expert hepatopathologist in assessing NAFLD using the NASH CRN scoring system. More studies are needed to investigate its suitability for community-based clinical practice.
Figures


References
-
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7. - PubMed
-
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. - PubMed
-
- Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;329:111–6. - PubMed
-
- Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23. - PubMed
-
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous